Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany

被引：0
|
作者：
Buecklein, Veit L. [1 ]
Ayuk, Francis A. [2 ]
Holderried, Tobias A. W. [3 ]
Mai, Christine [4 ]
Kievit, Bradley [5 ]
Blisset, Rob [5 ]
Doble, Brett [6 ]
Reid, Geoff [6 ]
Reimeir, Laura [7 ]
Bruns, Caroline [7 ]
Vadgama, Sachin [6 ]
机构：
[1] LMU Univ Hosp, Dept Med 3, Munich, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany
[3] Univ klinikum Bonn UKB, Bonn, Germany
[4] AplusA, Lyon, France
[5] Maple Hlth Grp LLC, New York, NY USA
[6] Gilead Co, Kite, Santa Monica, CA USA
[7] Gilead Sci GmbH, Munich, Germany
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-205589
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5037 / 5038
页数：2
相关论文
共 50 条
  • [1] Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy
    Di Rocco, Alice
    Di Rocco, Arianna
    Farcomeni, Alessio
    Petrucci, Luigi
    De Luca, Giulia
    Mazzon, Federico
    Martelli, Maurizio
    Foa, Robin
    BLOOD, 2019, 134
  • [2] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Dyer, Martin J. S.
    De Vos, Sven
    Ruan, Jia
    Flowers, Christopher
    Maddocks, Kami J.
    Rule, Simon
    Hamdy, Ahmed M.
    Izumi, Raquel
    Slatter, J. Greg
    Cheung, Jean
    Frigualt, Melanie M.
    Wei, Helen
    Mourya, Sanchita
    Hunder, Naomi N. H.
    Fowler, Nathan Hale
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Gatwood, Justin
    Masaquel, Anthony
    Ross, Ryan
    Sheinson, Danny
    Hossain, Farah
    Li, Jia
    James, Cameron
    Fox, David
    BLOOD, 2022, 140 : 7906 - 7907
  • [4] Analysis of Patterns of Failure and the Role of Bridging Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Treated with CAR T-Cell Therapy
    Ravella, R.
    Zhang-Velten, E. R.
    Awan, F.
    Rizvi, S.
    Shah, J. L.
    Desai, N. B.
    Geethakumari, P. Ramakrishnan
    Kumar, K. A., Jr.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E305 - E306
  • [5] Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)
    Bachanova, Veronika
    Tam, Constantine S.
    Borchmann, Peter
    Jaeger, Ulrich
    McGuirk, Joseph P.
    Holte, Harald
    Waller, Edmund K.
    Jaglowski, Samantha
    Bishop, Michael R.
    Andreadis, Charalambos
    Foley, Stephen Ronan
    Westin, Jason R.
    Fleury, Isabelle
    Ho, P. Joy
    Mielke, Stephan
    Teshima, Takanori
    Salles, Gilles
    Schuster, Stephen J.
    Maziarz, Richard T.
    Van Besien, Koen
    Izutsu, Koji
    Kersten, Marie Jose
    Magenau, John M.
    Wagner-Johnston, Nina D.
    Kato, Koji
    Corradini, Paolo
    Chu, Jufen
    Gershgorin, Irina
    Choquette, Therese
    Pacaud, Lida Bubuteishvili
    Jeschke, Margit
    BLOOD, 2019, 134
  • [6] Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany
    Skalt, Daniela
    Moertl, Bernhard
    von Bergwelt-Baildon, Michael
    Schmidt, Christian
    Schoel, Wolfgang
    Buecklein, Veit
    Weiglein, Tobias
    Dreyling, Martin
    Berger, Karin
    HEMASPHERE, 2022, 6 (07): : E736
  • [7] Clinical Pharmacology of CTL019 in Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
    Awasthi, Rakesh
    Tam, Constantine S.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Foley, Stephen Ronan
    Van Besien, Koen
    Wagner-Johnston, Nina D.
    Kersten, Marie Jose
    Schuster, Stephen J.
    Salles, Gilles Andre
    Maziarz, Richard Thomas
    Anak, Oezlem
    Pacaud, Lida Bubuteishvili
    Gazi, Lucien
    Waldron, Edward
    Hamilton, Jason
    Pruteanu, Iulian
    Tai, Feng
    Mueller, Karen Thudium
    Waller, Edmund K.
    BLOOD, 2017, 130
  • [8] Magrolimab in Combination with Rituximab plus Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Maakaron, Joseph
    Asch, Adam S.
    Popplewell, Leslie L.
    Collins, Graham P.
    Flinn, Ian W.
    Ghosh, Nilanjan
    Keane, Colin
    Ku, Matthew
    Mehta, Amitkumar
    Roschewski, Mark
    O'Hear, Carol
    Ren, Xuehan
    Villa, Bertha
    Lal, Indu
    Smith, Sonali M.
    Advani, Ranjana H.
    BLOOD, 2022, 140 : 3728 - 3730
  • [9] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Kalakonda, Nagesh
    Cavallo, Federica
    Follows, George
    Goy, Andre
    Vermaat, Joost S. P.
    Casasnovas, Olivier
    Lavee, Orly
    Maerevoet, Marie
    Zijlstra, Josee
    Bakhshi, Sameer
    Bouabdallah, Reda
    Choquet, Sylvain
    Gurion, Ronit
    Hill, Brian
    Jaeger, Ulrich
    Sancho, Juan-Manuel
    Schuster, Michael
    Thieblemont, Catherine
    De la Cruz, Fatima
    Egyed, Miklos
    Mishra, Sourav
    Offner, Fritz
    Vassilakopoulos, Theodoros
    Warzocha, Krzysztof
    McCarthy, Daniel
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Joshi, Anita
    Shah, Jatin
    Van den Neste, Eric
    Canales, Miguel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
  • [10] CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): A 'Real-World' Analysis of Patterns of Failure and Role of Bridging Therapy
    Ravella, Revathi
    Zhang-Velten, Elizabeth Ren
    Awan, Farrukh T.
    Rizvi, Syed M.
    Shah, Jennifer L.
    Desai, Neil B.
    Geethakumari, Praveen Ramakrishnan
    Kumar, Kiran A.
    BLOOD, 2020, 136
12345